Abstract 2096
Background
Primary malignancy of the heart are one of the rare tumors. This study aimed to show factors that affecting the survival rate of those patient with primary heart malignancy.
Methods
All 18 SEER registries database was used to obtain data of patient who diagnosed with primary malignant heart tumors between 2000 – 2013. One-year relative survival rates was by Kaplan-Meir method. We compared relative survival rates among groups of patients according to different variables.
Results
389 patients met the selection criteria in SEER database. The result showed that primary malignant heart tumors is most common in white race (75.6%), male gender (54.8%) and (40-79y) age group (62%). (>40 y) age group showed significant (P value =0.003) high one-year relative survival rate] 61% (51%-69.6%) [. Hemangiosarcoma (9120/3) was the most frequent histological type (29.3%). Although fibromyxosarcoma (8811/3) showed on of lowest frequent histological type, it shows high significant (P value =0.003) one-year relative survival rate] 83.8% (48.7%-95.7%) [. Overall comparison of different modalities of treatment showed insignificant difference (P value =0.094) of one-year relative survival rate. Although surgical intervention showed significant (P value > 0.001) increase in one-year relative survival rate] 67.1% (28.1%-88.2) [of moderately differentiated; Grade II cardiac cancer comparing with another treatment modalities. Also surgical intervention combined with radiotherapy showed significant (P value =0.007) increase in one year relative survival rate] 43% (14%-69.6%) [of poorly differentiated; Grade III cardiac cancer comparing with another treatment modalities].
Conclusions
Solitary surgical intervention modality of treatment is recommended in patient with grade II primary heart disease unlike combination of surgical intervention and radiotherapy with grad III of primary heart cancer which showed highest one-year survival rate.
Clinical trial identification
Legal entity responsible for the study
Eman Ramadan
Funding
None
Disclosure
All authors have declared no conflicts of interest.